Seagen’s breast cancer drug Tukysa turned down by NICENICE has decided not to recommend Seagen’s orally-active HER2 inhibitor Tukysa for advanced breast cancer in draft guidance, Share XSeagen’s breast cancer drug Tukysa turned down by NICEhttps://pharmaphorum.com/news/seagens-breast-cancer-drug-tukysa-turned-down-by-nice/
Enhertu nabs speedy FDA review for earlier use in breast cancerHard on the heels of impressive new data for Enhertu as a second-line therapy for breast cancer, AstraZeneca Share XEnhertu nabs speedy FDA review for earlier use in breast cancerhttps://pharmaphorum.com/news/enhertu-nabs-speedy-fda-review-for-earlier-use-in-breast-cancer/
ESMO21: Roche’s giredestrant takes stage in battle of the oral SERDsRoche has revealed the first phase 2 clinical data with giredestrant, one of a clutch of new selective Share XESMO21: Roche’s giredestrant takes stage in battle of the oral SERDshttps://pharmaphorum.com/news/esmo21-roches-giredestrant-takes-stage-in-battle-of-the-oral-serds/
NICE changes stance on Lilly’s breast cancer dug VerzeniosAfter rejecting Eli Lilly’s Verzenios for breast cancer therapy earlier this year, NICE has relented, recommending the drug Share XNICE changes stance on Lilly’s breast cancer dug Verzenioshttps://pharmaphorum.com/news/nice-changes-stance-on-lillys-breast-cancer-dug-verzenio/
HER2 heats up as Seagen licenses RemeGen ADC for $2.6bnSeagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate Share XHER2 heats up as Seagen licenses RemeGen ADC for $2.6bnhttps://pharmaphorum.com/news/her2-heats-up-as-seagen-licenses-remegen-adc-for-2-6bn/
Pfizer puts up $1bn to buy into Arvinas breast cancer programmePfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from Share XPfizer puts up $1bn to buy into Arvinas breast cancer programmehttps://pharmaphorum.com/news/pfizer-puts-up-1bn-to-buy-into-arvinas-breast-cancer-programme/
ASCO21: Lynparza aces adjuvant breast cancer therapy trialAstraZeneca and Merck & Co’s Lynparza is primed for even wider use in the treatment of breast cancer Share XASCO21: Lynparza aces adjuvant breast cancer therapy trialhttps://pharmaphorum.com/news/asco21-lynparza-aces-adjuvant-breast-cancer-therapy-trial/
AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecanAstraZeneca and Daiichi Sankyo have revealed new data from datopotamab deruxtecan in triple negative breast cancer (TNBC) – Share XAZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecanhttps://pharmaphorum.com/news/az-daiichi-unveil-data-from-tnbc-hopeful-datopotamab-deruxtecan/
Tecentriq can stay as therapy for triple-negative breast cancer, FDA experts sayRoche’s Tecentriq can stay on the US market as a therapy for triple negative breast cancer, advisers to Share XTecentriq can stay as therapy for triple-negative breast cancer, FDA experts sayhttps://pharmaphorum.com/news/tecentriq-can-stay-as-therapy-for-triple-negative-breast-cancer-fda-experts-say/
